What bioAffinity Technologies’ $4m financing means for CyPath Lung growth
bioAffinity Technologies closes $4 million financing as CyPath Lung sales grow. Examine dilution, cash runway and commercial expansion.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
How could CyPath Lung fit into pulmonary nodule evaluation after low-dose CT screening?
bioAffinity’s CyPath Lung framework targets pulmonary nodule decisions, but adoption still depends on prospective validation and payer support.
Medical Devices & Diagnostics
Can CyPath Lung sales growth turn bioAffinity Technologies into a viable diagnostics company?
Discover how bioAffinity Technologies’ CyPath Lung test is gaining physician adoption while clinical, reimbursement and funding risks remain.
Medical Devices & Diagnostics
Why bioAffinity’s CyPath Lung growth still leaves investors facing a hard cash question
CyPath Lung is gaining clinical traction. The harder test is whether bioAffinity can scale adoption before cash pressure tightens.
Medical Devices & Diagnostics
bioAffinity Technologies positions CyPath Lung as a confidence tool rather than a diagnostic replacement
Find out how bioAffinity Technologies’ CyPath Lung could reshape decision making for small lung nodules and what risks remain for adoption.